Ebola vaccine approved for use by the European Commission

The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.

Trial of Oxford COVID-19 vaccine in South Africa begins

COVID-19 Research

Participants in South Africa’s first clinical trial for a vaccine against COVID-19 are to be vaccinated this week.

Trial of Oxford COVID-19 vaccine starts in Brazil

COVID-19 Research

Volunteers have begun taking part in Latin America’s first clinical trial for a vaccine against COVID-19.

The Duke of Cambridge visits Oxford Vaccine Centre

COVID-19

The Duke of Cambridge visits the University of Oxford’s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

COVID-19 Research

AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.

Alice in Typhoidland wins film trophy

Awards & Appointments Public Engagement

Bristol Science Film Festival awarded the Professional Science Fact Film Prize to "The Adventures of Alice in Typhoidland" co-created by the Oxford Vaccine Group.

Oxford COVID-19 vaccine to begin phase II/III human trials

COVID-19 Research

Oxford Vaccine Group researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.

Funding and manufacturing boost for UK vaccine programme

COVID-19 Research

The Government has announced £65.5 million of new funding for the vaccine being developed at the Oxford Vaccine Group as coronavirus vaccine trials accelerate.

Landmark partnership announced for development of COVID-19 vaccine

COVID-19 Research

The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the Oxford Vaccine Group.

Oxford COVID-19 vaccine begins human trial stage

COVID-19 Research

University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.

Paediatrics project receives funding to assess novel coronavirus infection rates in children and teenagers across the UK

Awards & Appointments COVID-19 Research

A multi-site project, called ‘What’s the STORY?’ has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research’s (NIHR) Urgent Public Health Response.

Funding for new COVID-19 studies awarded to OVG's project on infectious disease immunity in children

Awards & Appointments COVID-19 Research

Five projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.

Oxford COVID-19 vaccine programme opens for clinical trial recruitment

COVID-19 Research

University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still.

COVID-19 vaccine development

COVID-19 Research

A vaccine candidate for COVID-19 has been identified by researchers from the Oxford Vaccine Group and Oxford's Jenner Institute.

Alice in Typhoidland: Join Lewis Carroll’s Alice on a journey through the story of typhoid, from Victorian sewer systems to cutting-edge scientific research

Public Engagement

A new exhibition tells the story of Oxford’s role in the fight against typhoid, from pioneering efforts to eliminate typhoid in the era of Lewis Carroll’s Alice in Wonderland to game-changing present-day vaccine trials.

Typhoid vaccine over 81% effective in tackling disease in Nepal

Research

A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting.

Ebola vaccine approved as second jab trialled

It’s very exciting to see that the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine schedule is being used in a large-scale study in the Democratic Republic of Congo. This is an important step towards having multiple vaccine strategies available to fight this dreadful illness, as is the recent application for marketing authorisation of this schedule by the European Medicines Agency.

Typhoid: A ghost of the past that never really went away

For most people living in the United States and Europe, typhoid is a distant memory, a ghost of a disease from another time. But typhoid never disappeared. For many people living in low- and middle-income countries, typhoid is endemic and an all too common risk faced predominately by children.

Decades neglecting an ancient disease has triggered a health emergency around the world

OVG researcher gives both modern and historical perspectives on typhoid outbreaks in her latest article for The Conversation.

International neglect of typhoid outside rich countries threatens a new global health emergency

The emergence of untreatable strains of typhoid threatens a new global health emergency that requires urgent collective action, argue experts from the Oxford Martin School in the journal Clinical Infectious Diseases today.

Load More